Sputnik V demonstrates strong protection against Omicron variant
Previous studies also demonstrated additional significant strengthening of protection against Omicron by Sputnik Light…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
medRxiv
Phase I clinical trial outcome shows Covaxin generates antibody, T-cell memory response
we hypothesize that BBV152 can generate antibodies that may persist for 6-12 months.